Prevalence of preclinical Alzheimer disease: Comparison of current classification systems

Silke Kern, Henrik Zetterberg, Jürgen Kern, Anna Zettergren, Margda Waern, Kina Höglund, Ulf Andreasson, Hanna Wetterberg, Anne Börjesson-Hanson, Kaj Blennow, Ingmar Skoog, Silke Kern, Henrik Zetterberg, Jürgen Kern, Anna Zettergren, Margda Waern, Kina Höglund, Ulf Andreasson, Hanna Wetterberg, Anne Börjesson-Hanson, Kaj Blennow, Ingmar Skoog

Abstract

Objective: To determine the prevalence of preclinical Alzheimer disease (AD) according to current classification systems by examining CSF from a representative general population sample of 70-year-olds from Gothenburg, Sweden.

Method: The sample was derived from the population-based H70 Gothenburg Birth Cohort Studies in Gothenburg, Sweden. The participants (n = 322, age 70 years) underwent comprehensive neuropsychiatric, cognitive, and somatic examinations. CSF levels of β-amyloid (Aβ)42, Aβ40, total tau, and phosphorylated tau were measured. Preclinical AD was classified according to criteria of the A/T/N system, Dubois 2016, National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, and International Working Group-2 (IWG-2) criteria. Individuals with Clinical Dementia Rating score >0 were excluded, leaving 259 cognitively unimpaired individuals.

Results: The prevalence of amyloid pathology was 22.8%, of total tau pathology was 33.2%, and of phosphorylated tau pathology was 6.9%. With the A/T/N system, the prevalence of A+/T-/N- was 13.1%, A+/T-/N+ was 7.3%, A+/T+/N+ was 2.3%, A-/T-/N+ was 18.9%, and A-/T+/N+ was 4.6%. When the Dubois criteria were applied, the prevalence of asymptomatic at risk for AD was 36.7% and of preclinical AD was 9.7%. With the NIA-AA criteria, the prevalence of stage 1 was 13.1% and stage 2 was 9.7%. With the IWG-2 criteria, the prevalence of asymptomatic at risk for AD was 9.7%. The APOE ε4 allele was associated with several of the categories. Men more often had total tau pathology, A+/T-/N+, preclinical AD according to Dubois 2016, asymptomatic at risk for AD according to the IWG-2 criteria, and NIA-AA stage 2.

Conclusion: The prevalence of pathologic AD markers was very common (46%) in a representative population sample of 70-year-olds. The clinical implications of these findings need to be scrutinized further in longitudinal studies.

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure. Venn diagram
Figure. Venn diagram
Venn diagram of the ATN distribution of amyloid and tau pathology according to the A/T/N classification scheme in a representative population-based sample of 70-year-olds with a Clinical Dementia Rating score of 0. A+ refers to Aβ pathology (CSF Aβ42 levels ≤530 pg/mL), T+ to pathologic p-tau (CSF p-tau ≥ 80 pg/mL), and N+ to neurodegeneration biomarker (CSF total tau ≥350 pg/mL) in 259 cognitively normal elderly all 70 years of age. Aβ = β-amyloid; p-tau = phosphorylated tau.

References

    1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387–403.
    1. Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci 1968;7:331–356.
    1. Neuropathology Group, Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales: Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357:169–175.
    1. Aizenstein HJ, Nebes RD, Saxton JA, et al. . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509–1517.
    1. Jack CR Jr, Lowe VJ, Weigand SD, et al. . Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355–1365.
    1. Pike KE, Savage G, Villemagne VL, et al. . Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837–2844.
    1. Dubois B, Feldman HH, Jacova C, et al. . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–629.
    1. Vos SJ, Gordon BA, Su Y, et al. . NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 2016;44:1–8.
    1. Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957–965.
    1. Hoglund K, Kern S, Zettergren A, et al. . Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry 2017;7:e995.
    1. Stomrud E, Minthon L, Zetterberg H, Blennow K, Hansson O. Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: a prospective 9-year study. Alzheimers Dement (Amst) 2015;1:403–411.
    1. Bateman RJ, Xiong C, Benzinger TL, et al. . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804.
    1. Fagan AM, Head D, Shah AR, et al. . Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65:176–183.
    1. Sutphen CL, Jasielec MS, Shah AR, et al. . Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 2015;72:1029–1042.
    1. Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–216.
    1. Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87:539–547.
    1. Dubois B, Hampel H, Feldman HH, et al. . Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12:292–323.
    1. Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–292.
    1. Jack CR Jr, Knopman DS, Weigand SD, et al. . An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765–775.
    1. Skoog I, Borjesson-Hanson A, Kern S, et al. . Decreasing prevalence of dementia in 85-year olds examined 22 years apart: the influence of education and stroke. Sci Rep 2017;7:6136.
    1. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153–158.
    1. Kern S, Skoog I, Ostling S, Kern J, Borjesson-Hanson A. Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women. BMJ Open 2012:2:e001288.
    1. Kern J, Kern S, Blennow K, et al. . Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology 2016;87:1674–1680.
    1. Bjerke M, Kern S, Blennow K, et al. . Cerebrospinal fluid fatty acid-binding protein 3 is related to dementia development in a population-based sample of older adult women followed for 8 years. J Alzheimers Dis 2016;49:733–741.
    1. Vanmechelen E, Vanderstichele H, Davidsson P, et al. . Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49–52.
    1. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–245.
    1. Andreasen N, Hesse C, Davidsson P, et al. . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673–680.
    1. Steen Jensen C, Portelius E, Siersma V, et al. . Cerebrospinal fluid amyloid beta and tau concentrations are not modulated by 16 weeks of moderate- to high-intensity physical exercise in patients with Alzheimer disease. Demen Geriatr Cogn Disord 2016;42:146–158.
    1. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. . Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403–413.
    1. Rowe CC, Ellis KA, Rimajova M, et al. . Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275–1283.
    1. Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol 2017;16:435–444.
    1. Crary JF, Trojanowski JQ, Schneider JA, et al. . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755–766.
    1. Wang HF, Tan L, Cao L, et al. . Application of the IWG-2 diagnostic criteria for Alzheimer's disease to the ADNI. J Alzheimers Dis 2016;51:227–236.
    1. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015;313:1939–1949.
    1. Jansen WJ, Ossenkoppele R, Knol DL, et al. . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924–1938.
    1. Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol 2015;72:511–519.
    1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119–1122.
    1. van Harten AC, Smits LL, Teunissen CE, et al. . Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013;81:1409–1416.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj